Coherus Biosciences Inc
Research Coherus Biosciences Inc (CHRS) on Bullrun: market cap USD 211.62M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCHRS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 211.62M
- Financial periodQ2 2026
- RevenueUSD 14.31M
- Net income-USD 20.63M
- Free cash flow-USD 62.09M
- Gross margin70.4%
Valuation Snapshot
latest market cap is USD 211.62M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 42.17M | USD 168.02M | -USD 138.51M | 67.2% | 1.43 | USD 88.88M | USD 40.34M | USD 61.01M |
| FY2024 | USD 26.39M | USD 28.51M | -USD 20.44M | 66.9% | 0.25 | USD 125.99M | USD 269.90M | -USD 131.99M |
| FY2023 | USD 1.22M | -USD 237.89M | -USD 175.17M | 64.0% | -2.53 | USD 102.89M | USD 480.84M | -USD 193.43M |
| FY2022 | USD 211.04M | -USD 291.75M | -USD 243.16M | 66.8% | -3.76 | USD 63.55M | USD 480.72M | -USD 137.42M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 211.62M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 172.04M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 159.55M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 370.84M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 616.00M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.23B | n/a | n/a | n/a |
About Coherus Biosciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Coherus Biosciences Inc's market cap?
Coherus Biosciences Inc's market capitalization is USD 211.62M.
What does Coherus Biosciences Inc do?
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.